Back to top
more

Galectin Therapeutics (GALT)

(Delayed Data from NSDQ)

$3.05 USD

3.05
78,825

-0.06 (-1.93%)

Updated May 23, 2024 04:00 PM ET

After-Market: $3.04 -0.01 (-0.33%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GALT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galectin Therapeutics Inc. [GALT]

Reports for Purchase

Showing records 81 - 100 ( 107 total )

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 81

09/28/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 82

09/28/2016

Company Report

Pages: 6

NASH Phase 2 Study Fails;Downgrading to Sell; PT to $0.75

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 83

08/29/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 84

08/29/2016

Company Report

Pages: 7

Psoriasis Is Close But No Cigar, NASH Data on Track for September

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 85

08/26/2016

Company Report

Pages: 5

Exploratory Trial in Psoriasis Shows Benefit Is Not Good Enough; Focus Remains on NASH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 86

08/15/2016

Company Report

Pages: 9

2Q16 Recap: Looking to Positive NASH-FX Data in September as a Catalyst; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 87

08/03/2016

Daily Note

Pages: 4

NASH-CX Trial Recruitment Complete; Affirm Buy Ahead of NASH-FX Data in September

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 88

07/01/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 89

07/01/2016

Company Report

Pages: 12

We are resuming coverage with a Buy rating and a $3 price target

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 90

05/17/2016

Daily Note

Pages: 3

Early Look at Exploratory Phase 2 Study Suggests Activity in Psoriasis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 91

05/12/2016

Company Report

Pages: 6

Enrollment Complete in NASH-FX, Readout Expected in September; 1Q16 Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 92

04/12/2016

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 93

03/28/2016

Company Report

Pages: 8

Reversing Fibrosis in NASH; Assuming Coverage with a Buy Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 94

03/09/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 95

03/08/2016

Company Report

Pages: 38

Prevent and Reverse

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 75.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 96

03/03/2016

Company Report

Pages: 5

NASH-CX and NASH-FX Trials On Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 97

11/25/2015

Company Report

Pages: 5

Two Phase 2 NASH Trials Ongoing; Capital Raised; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 98

09/28/2015

Company Report

Pages: 6

Phase 2a Psoriasis Study Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 99

09/21/2015

Company Report

Pages: 35

Reversing NASH Fibrosis and Cirrhosis; Initiate with Buy and $7 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 75.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 100

04/21/2014

Company Report

Pages: 4

We are suspending coverage in order to focus on other areas of interest to our institutional clients.

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 10.00

Research Provided by a Third Party